Early initiation of renin–angiotensin–aldosterone system inhibitors (RAASis) is reported to delay progression of several forms of familial FSGS and SRNS; however, no cases involving ACTN4 mutations have been reported. This evidence concerns the gene ACTN4 and focal segmental glomerulosclerosis.